Search Results

SRI-011381 25 mg  | 99.11%

TargetMol

SRI-011381, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer’s disease.

More Information Supplier Page

SRI-011381 10 mg  | 99.11%

TargetMol

SRI-011381, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer’s disease.

More Information Supplier Page

SRI-011381 5 mg  | 99.11%

TargetMol

SRI-011381, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer’s disease.

More Information Supplier Page

Bilastine 50 mg  | Purity Not Available

TargetMol

Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.

More Information Supplier Page

Delpazolid 1 mg  | 99.87%

TargetMol

Delpazolid, also known as LCB01-0371, is a new oxazolidinone with cyclic amidrazone. In vitro activity of LCB01-0371 against 624 clinical isolates was evaluated and compared with those of linezolid, vancomycin, and other antibiotics. LCB01-0371 showed good activity against Gram-positive pathogens. In vivo activity of LCB01-0371 against systemic infections in mice was also evaluated. LCB01-0371 was […]

More Information Supplier Page

AST 487 25 mg  | 98.17%

TargetMol

AST 487 is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.

More Information Supplier Page

Bilastine 100 mg  | Purity Not Available

TargetMol

Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.

More Information Supplier Page